Clinical Trials

CRC

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT05566223 2026-02-23

CheckCell-2

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06829199 2026-02-19

MK-5890-003

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05846724 2026-01-22

PULSAR

Sarcoma

Sarcoma, Kaposi

NCT04129515 2026-01-02

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Dermatologic

Melanoma

NCT05668949 2025-12-17

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06116578 2025-12-01

NeoSarc

Sarcoma

Liposarcoma, Neoplasms, Sarcoma

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Prostatic Neoplasms

NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

CNS

Glioblastoma

NCT06498518 2025-07-11

PRIMUS006

Gastrointestinal

Pancreatic Neoplasms

NCT05879484 2025-07-10

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT04569461 2025-07-04

TALON

Prostatic Neoplasms

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT06190249 2025-06-05

LN-144

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT04418219 2025-04-29

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer